XL647: Phase III started

Kadmon began a double-blind, placebo-controlled, U.S. Phase III trial to compare once-daily 300 mg oral KD019 vs. once-daily 150 mg oral Tarceva erlotinib in about 620 patients with stage IIIB/IV NSCLC who have progressed after first- or second-line chemotherapy. The trial will use the VeriStrat test from Biodesix Inc. (Broomfield, Colo.) to identify biomarkers of response to KD019. Biodesix markets VeriStrat to identify patients with advanced NSCLC who are likely to have good or poor outcomes after treatment with EGFR inhibitors. ...